Abbott receives CE mark for ovarian cancer detection equipment

Abbott has been granted conformite Europeene (CE) certification for its ovarian cancer detection test, it revealed this week.

The pharmaceutical company is now authorised to distribute its ARCHITECT human epididymis protein 4 (HE4) test in Europe – a piece of equipment that is capable of determining whether a pelvic mass has either malignant or benign properties.

It operates using a blood analysis to assist in the diagnosis of epithelial ovarian cancer and will run on Abbott’s ARCHITECT system.

According to Abbott, it is the only automated HE4 test available in the world.

Michael Warmuth, senior vice-president of diagnostics the firm, commented: “Abbott’s ARCHITECT HE4 test will aid physicians in determining the most appropriate treatment for their patients.”

In similar news, the organisation announced earlier this week that it has also received the CE mark for its colorectal cancer test, the RealTime mS9 – a non-invasive DNA assay that detects the methylated form of Septin 9 in blood specimens.